| Hazard Information | Back Directory | [Uses]
LH1753 is an orally active L-cystine crystallization inhibitor with an EC50 of 29.5 nM. LH1753 can be used for Cystinuria research[1]. | [in vivo]
LH1753 (150 μmol/kg, i.g., QD for 8 weeks) inhibits the L-cystine stone formation and has no effect on the growth of Slc3a1-knockout mouse model of cystinuria[1].
| [References]
[1] Longqin Hu, et al. 8-l-Cystinyl Bis(1,8-diazaspiro[4.5]decane) as an Orally Bioavailable l-Cystine Crystallization Inhibitor for Cystinuria, ACS Medicinal Chemistry Letters, Article ASAP |
|
|